« Targeting IL23p19 Using Risankizumab for the Management of Moderate-to-Severely Active Crohn’s Disease: The Next Frontier? ». Canadian IBD Today, vol. 1, nᵒ S05, mai 2023, p. 2–7, https://doi.org/10.58931/cibdt.2023.1S0510.